Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on June 5, 2018. The filing reports the appointment of a new member to the Board of Directors and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of John K. Jenkins, MD, to the Board of Directors, effective June 5, 2018. Dr. Jenkins brings significant regulatory experience, having served as Director of the Office of New Drugs at the FDA until his retirement in January 2017.
Compensation and Governance Details
- Role: Non-employee Director.
- Term: Until the next annual meeting of shareholders or until a successor is elected.
- Compensation Package:
- Initial stock option grant to purchase 68,000 shares of common stock.
- Annual cash retainer fee of $35,000 (pro-rated for the current year).
- Annual stock option grant to purchase shares of common stock.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Jenkins, covering expenses, judgments, and penalties incurred in connection with his services as a director.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 68,000 initial option grant.
- Review the Company's standard non-employee director compensation plan for details on the annual stock option grant formula.
- Confirm the date of the next annual meeting of shareholders to determine the initial term length.
- Check for any potential conflicts of interest given Dr. Jenkins' recent role at Greenleaf Health and his extensive FDA history.